ArticleJournal of Brown hospital medicine2025
Splenic Infarction in Babesiosis: A Case Series.
Article in Journal of Brown hospital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Underlying thrombotic conditions in patients with splenic infarction: a 10-year retrospective analysis.Thrombosis journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Babesiosis is an intraerythrocytic tick-borne illness with a rising incidence in the northeastern United States that can be complicated by splenic infarction and atraumatic rupture. We report three cases of splenic infarcts and pose the question: Should certain patients with Babesia species-induced splenic infarcts receive therapeutic anticoagulation? Splenic infarct, with or without rupture, is a rare yet increasingly reported complication of babesiosis. This complication does not appear to be correlated with the degree of parasitemia. There are no guidelines for the management of Babesia species-induced splenic infarcts. While therapeutic anticoagulation may be indicated for splenic infarcts due to other etiologies, the decision to anticoagulate patients with babesiosis remains on a case-by-case basis, as the mechanism of infarct-thrombus formation, coagulation system activation, or red blood cell sequestration-remains unknown. Future studies may be warranted to elucidate the mechanism of splenic infarction secondary to babesiosis, as well as to assess the safety and efficacy of anticoagulation use. Clinicians must be aware of the risk of splenic infarction in Babesia species infections. We report three cases of infection complicated by splenic infarct and discuss the role of anticoagulation. The decision to anticoagulate is individualized and determined by clinical features such as the presence of infarct-related symptoms and overall bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.